AUR103 Calcium

DRUG2 trials

Sponsors

Aurigene Discovery Technologies Limited

Conditions

Advanced NET of GI OriginGastroesophageal Junction AdenocarcinomaHER 2 Positive Gastric CancerNeuroendocrine (NE) Tumors

Phase 1

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

TerminatedNCT07040059

Aurigene Discovery Technologies LimitedGastroesophageal Junction Adenocarcinoma, HER 2 Positive Gastric Cancer

Start: 2025-03-22End: 2025-12-29Updated: 2026-04-17

Phase 2

AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)

Not yet recruitingNCT07640737

Aurigene Discovery Technologies LimitedAdvanced NET of GI Origin, Neuroendocrine (NE) Tumors

Start: 2026-06-30End: 2029-01-31Target: 30Updated: 2026-06-11